Compare American International Group Inc (AIG) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American International Group Inc vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? American International Group Inc trades at $80 (market cap $42.98B), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $283.83 (market cap $7.85B). The key difference: American International Group Inc is far larger — about 5.5× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and American International Group Inc pays a 2.47% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| AIG | BIO | |
|---|---|---|
Market Cap | $42.98B | $7.85B |
Sector | Financials | Health |
52-Week High | $86.59 | $339.75 |
52-Week Low | $71.89 | $241.71 |
Enterprise Value | $50.68B | $7.66B |
Dividend Yield | 2.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIG trades at $81.06, up 2.1% today, showing strong momentum with three consecutive quarterly earnings beats. The stock is supported by bullish technical signals and a consensus price target of $88.13. Recent executive appointments and the acquisition of Everest Colombia signal strategic growth initiatives. Revenue stabilized around $26.8B in 2025 with net income margin improving to 11.88%.
Outlook remains positive with earnings growth and expansion in Latin America offering upside potential. Risks include catastrophe exposure and competitive pressures. Analysts are predominantly neutral with 58.5% Hold ratings, suggesting cautious optimism amid solid fundamentals.
BIO trades at $292.50, down 1.47% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported revenue of $2.58B for 2025 with net income of $759.90M, though it missed EPS estimates for three consecutive quarters. Positive cash flow from operations of $532.20M supports financial health, while recent news highlights Nasdaq compliance and industry participation.
Outlook remains cautiously optimistic with a consensus price target of $305.00, representing ~4% upside. Risks include consistent earnings misses and high P/E of 49.11, but strong analyst buy sentiment (53.85%) and improving profitability margins offer potential for recovery if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American International Group Inc
American International Group is one of the largest insurance and financial services firms in the world and has a global footprint. It operates through a wide range of subsidiaries that provide property, casualty, and life insurance. Its revenue is split roughly evenly between commercial and consumer lines.
Read more on AIG →About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →
